Literature DB >> 15838519

Getting in and out of mitosis with Polo-like kinase-1.

Marcel A T M van Vugt1, René H Medema.   

Abstract

Research in different species has shown that Polo-like kinases are essential for successful cell division. In human cells, Polo-like kinase-1 (Plk1) has been implicated in the regulation of different processes, including mitotic entry, spindle formation and cytokinesis. Recently, a range of new downstream targets of Plk1 has been identified, as well as a molecular mechanism that explains recruitment of Plk1 to potential substrate proteins through its polo-box domain. On the basis of these reports, we discuss possible mechanisms by which Polo-like kinases can exert their multiple functions during mitosis. Polo-like kinases also function in DNA damage checkpoints. Plk1 has been shown to be a target of the G2 DNA damage checkpoint, while Cdc5, the Polo-like kinase in Saccharomyces cerevisiae, has long been known to be required for adaptation to persistent DNA damage. Just recently, a similar requirement for Polo-like kinases during checkpoint adaptation was demonstrated in multicellular organisms. Moreover, Plk1 was also shown to be required for checkpoint recovery following checkpoint inactivation, that is, in cells where the damage is completely repaired. Thus, Plk1 appears to play a role at multiple points during a restart of the cell cycle following DNA damage. Based on these novel observations, we discuss possible consequences of using Plk1 as a target in anticancer strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15838519     DOI: 10.1038/sj.onc.1208617

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  112 in total

1.  Chromosome misalignments induce spindle-positioning defects.

Authors:  Mihoko A Tame; Jonne A Raaijmakers; Pavel Afanasyev; René H Medema
Journal:  EMBO Rep       Date:  2016-02-04       Impact factor: 8.807

2.  Plk1 phosphorylation of IRS2 prevents premature mitotic exit via AKT inactivation.

Authors:  Long Chen; Zhiguo Li; Nihal Ahmad; Xiaoqi Liu
Journal:  Biochemistry       Date:  2015-04-06       Impact factor: 3.162

3.  Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.

Authors:  Anna Santamaria; Rüdiger Neef; Uwe Eberspächer; Knut Eis; Manfred Husemann; Dominik Mumberg; Stefan Prechtl; Volker Schulze; Gerhard Siemeister; Lars Wortmann; Francis A Barr; Erich A Nigg
Journal:  Mol Biol Cell       Date:  2007-08-01       Impact factor: 4.138

4.  Evidence for regulation of mitotic progression through temporal phosphorylation and dephosphorylation of CK2alpha.

Authors:  Nicole A St-Denis; D Richard Derksen; David W Litchfield
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

5.  Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.

Authors:  Özge Saatci; Simone Borgoni; Özge Akbulut; Selvi Durmuş; Umar Raza; Erol Eyüpoğlu; Can Alkan; Aytekin Akyol; Özgür Kütük; Stefan Wiemann; Özgür Şahin
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

6.  Acetylated lysine 56 on histone H3 drives chromatin assembly after repair and signals for the completion of repair.

Authors:  Chin-Chuan Chen; Joshua J Carson; Jason Feser; Beth Tamburini; Susan Zabaronick; Jeffrey Linger; Jessica K Tyler
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

7.  Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry.

Authors:  Akiko Seki; Judith A Coppinger; Chang-Young Jang; John R Yates; Guowei Fang
Journal:  Science       Date:  2008-06-20       Impact factor: 47.728

8.  Multiplexed random peptide library and phospho-specific antibodies facilitate human polo-like kinase 1 inhibitor screen.

Authors:  Kenji Tanaka; Mitsunori Koresawa; Masato Iida; Kazuhiro Fukasawa; Erica Stec; Jason Cassaday; Peter Chase; Keith Rickert; Peter Hodder; Toshimitsu Takagi; Hideya Komatani
Journal:  Assay Drug Dev Technol       Date:  2010-02       Impact factor: 1.738

9.  Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass.

Authors:  Gina Chun; Dongsoon Bae; Kristen Nickens; Travis J O'Brien; Steven R Patierno; Susan Ceryak
Journal:  Carcinogenesis       Date:  2010-01-20       Impact factor: 4.944

10.  The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.

Authors:  Elizabeth M Matthew; Lori S Hart; Aristotelis Astrinidis; Arunasalam Navaraj; Nathan G Dolloff; David T Dicker; Elizabeth P Henske; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2009-12-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.